Multidisciplinary Approach to Disease Management

Commentary
Video

Valerie Frank and Sara M. Tolaney, MD, MPH, share advice for patients on managing treatment with antibody-drug conjugates and the importance of participating in clinical trials for HR+/HER2- metastatic breast cancer.

Transcript

I had chemo I had a lumpectomy followed by another surgery because I had bad margins. And then two more surgeries, one of which was because I had a hole that appeared in my breast. And then another one, then the hole reappeared and a wound care surgeon at the Brigham (and Women’s Hospital) did another surgery to close that wound. So I ended up having like the most surgeries, anyone could have for mastectomy.

And I had radiation and then I thought, OK, I knew that I was high risk for to recur. I think I always thought the odds were about 40% based on what I had written a read. And so that all happened like in 2018-2019. And then, in January, New Year's Eve … that New Year's Eve, I was in a lot of back pain, and it just kind of came out of nowhere I like I called my oncologist, we had scans. And I had metastases to the liver — pretty severe metastases to the liver. Lung bones someplace else. … Lots of cancer everywhere. Super bad stage 4.

I can't even describe how horrible that was. I was in treatment for just what felt like a lot longer than most people because I had such a disastrous experience with surgeries. My surgeon is amazing. And I adore her. And it just I just kept having the worst luck. And it was just a, I think I was in treatment for like, a year. It was just, it was just a really long time. It was a lot of chemo. The chemo was brutal. surgeries, radiation …

At some point, my oncologist at the time, a different oncologist than Dr. Tolaney said, “OK, well, you know, we've done everything for you that we can do. And now you're just going to check in every six months, or every year. and I was like, shocked. And I was only in that state for, I don't know, to one to two years, I would not a long time. And the entire time, I was terrified that it would come back, and it did. I was very sick. When the cancer came back. My liver was in terrible shape. And Dr. Tolaney and Jason will have to my husband will have to remind me of what we did first what treatment we did first. It was, I believe it was I don't remember the name of it. But it did not work. It did not work. It was pills. It didn't work. hormonal therapy, which didn't work. Yeah, it didn't work. So then. And I was very kind of emotionally beaten down, partly because I was in a lot of pain. I was in a lot, a lot, a lot of pain.

The palliative care team at Dana-Farber with Dr. Randolph was pretty amazing and trying to take care of me. But I was in a lot of pain all the time. And, and then we tried something else that worked. Xeloda. So it was really wonderful and I and it allowed me to live kind of a normal-ish life. It started to work. And it worked for some number of months, until it did not. And then it was time to make a change to another treatment.

I tend to feel incredibly defeated when a treatment stops working. And it's a real testament to how wonderful my team is that they've been able to like talk me down off of a ledge every time a treatment stops working and try to tell me like this is what happens and treatments work and then they don't and then we make a change and we're going to get you back and you know what, what usually precedes the change though is kind of falling apart. physically for a little bit.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Dr. Andrea Apolo in an interview with CURE
Dr. Kim in an interview with CURE
Dr. Nguyen, from Stanford Health, in an interview with CURE
Dr. Barzi in an interview with CURE
Sue Friedman in an interview with CURE
Dr. Giles in an interview with CURE
Related Content